Epcoritamab and glofitamab as bridging therapy prior to CAR T-cell therapy in relapsed/refractory large B-cell lymphoma. // Blood Immunology & Cellular Therapy. – URL: https://www.sciencedirect.com/science/article/pii/S3050597626000606?dgcid=rss_sd_all
Epcoritamab and glofitamab as bridging therapy prior to CAR T-cell therapy in relapsed/refractory large B-cell lymphoma. Blood Immunology & Cellular Therapy. https://www.sciencedirect.com/science/article/pii/S3050597626000606?dgcid=rss_sd_all
“Epcoritamab and glofitamab as bridging therapy prior to CAR T-cell therapy in relapsed/refractory large B-cell lymphoma.” Blood Immunology & Cellular Therapy.
@article{article38112,
title = {Epcoritamab and glofitamab as bridging therapy prior to CAR T-cell therapy in relapsed/refractory large B-cell lymphoma},
journal = {Blood Immunology \& Cellular Therapy},
url = {https://www.sciencedirect.com/science/article/pii/S3050597626000606?dgcid=rss_sd_all}
}
Publication date: November–December 2026 Source: Acta Otorrinolaringologica (English Edition), Volume 77, Issue 6 Author(s): Daniel Álvarez de Castro, Sandra Pérez de la Iglesia, Miguel Ramírez Verdyguer, Francisco José Manzano Gómez